Dentsply Earnings: Soft Demand and Byte Suspension Dampen Outlook, but Selloff Is an Overreaction

No-moat Dentsply Sirona’s third-quarter results were in line with our expectations. Total sales of $950 million was roughly flat year over year, and adjusted EPS reflected low-single-digit growth. However, the firm cited persistent macro challenges in dentistry from key markets like the US and Germany, and pressure is lingering longer than we had originally anticipated. Against this difficult backdrop, management lowered its full-year 2024 guidance and now expects $3.81 billion of sales at midpoint, about a 2% reduction from the previous figure, and EPS of $1.84 at midpoint, an 8% reduction from the prior outlook. We think the downward outlook revision coupled with the firm’s near-term uncertainty are causing investors to lose confidence in the firm. Shares heavily sold off after the release and closed down about 28%. After digesting Nov. 7’s news, we've raised the firm’s Uncertainty Rating to High from Medium and lowered our fair value estimate to $23.50 per share from $27.